Garden City, New York 11530

  • Brain and Central Nervous System Tumors


RATIONALE: Radioactive drugs such as phosphorus 32 may be able to kill tumor cells. PURPOSE: This phase I trial is studying the side effects and best dose of phosphorus 32 in treating patients with glioblastoma multiforme.

Study summary:

OBJECTIVES: - Determine the dosimetry toxicity of interstitial colloidal phosphorus P32 (C P32) in patients with recurrent or poor prognosis grade 4 astrocytoma. - Determine the maximum tolerated dose of C P32 administered directly into the tumor of these patients. - Determine the maximum tolerated fractionated dose of interstitial C P32 in these patients. - Determine the therapeutic response rate to the acceptable single and fractionated doses of C P32 in these patients. OUTLINE: This is a dose-escalation study. Patients receive interstitial colloidal phosphorus P32 (C P32) on day 0. Courses repeat every 4-6 weeks in the absence of disease progression or unacceptable toxicity. Cohorts of 3 patients receive escalating doses of C P32 until the maximum tolerated dose (MTD) is determined. The MTD is defined the dose at which 2 of 3 patients experience dose-limiting toxicity. Patients are followed at 1, 2, 4, 6, 9, 15, and 24 weeks. PROJECTED ACCRUAL: A minimum of 12 patients will be accrued for this study.


DISEASE CHARACTERISTICS: - Histologically proven grade 4 astrocytoma (glioblastoma) - Failed external beam radiotherapy and/or surgery OR - Poor prognosis disease - No clinical evidence of metastatic disease within the CNS other than the primary tumor site - Stereotactic biopsy or gross total excision with residual tumor - Lesion 3 to 5 cm in size - No spinal cord tumor(s) PATIENT CHARACTERISTICS: Age: - 18 and over Performance status: - Karnofsky 70-100% Life expectancy: - Not specified Hematopoietic: - WBC at least 3,000/mm3 - Neutrophil count at least 1,900/mm3 - Platelet count at least 100,000/mm3 - Hemoglobin at least 9 g/dL (transfusion allowed) Hepatic: - Not specified Renal: - Creatinine no greater than 1.5 mg/dL - BUN less than 25 mg/dL Other: - Not pregnant - Negative pregnancy test - Fertile patients must use effective contraception PRIOR CONCURRENT THERAPY: Biologic therapy: - Not specified Chemotherapy: - Not specified Endocrine therapy: - Not specified Radiotherapy: - See Disease Characteristics Surgery: - See Disease Characteristics



Primary Contact:

Study Chair
Stanley E. Order, MD, ScD, FACR
Center for Molecular Medicine

Backup Contact:


Location Contact:

Garden City, New York 11530
United States

Stanley E. Order, MD, ScD, FACR
Phone: 516-222-5190

Site Status: Recruiting

Data Source:

Date Processed: December 07, 2022

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

This study is not currently recruiting Study Participants on The form below is not enabled.